HEPATITIS B IMMUNOGLOBULIN P BEHRING
CSL BEHRING
Identification
- Active ingredient (INN)
- IMMUNOGLOBULINE HUMAINE DE L'HEPATITE B
- Internal code
- 13 V 505
- Country of Origin
- Germany
- Pharmaceutical form
- IM Injectable Solution (Pre-filled Syringe)
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/1 seringue pre-remplie de 1ml
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
Long-term hepatitis
B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B.
Therefore, the hepatitis-B vaccines are cancer-preventing vaccines.
According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine.
HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen.
It is extracted from the Cohn fraction II.
During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed.
The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus.
Indications
Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
Mechanism of Action
In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.